<DOC>
	<DOCNO>NCT02537535</DOCNO>
	<brief_summary>Cross-sectional observational study design identify describe care gap guideline-oriented low density lipoprotein cholesterol ( LDL-C ) management Canadian patient high cardiovascular risk .</brief_summary>
	<brief_title>Guidelines Oriented Approach Lipid Lowering ( GOAL ) Canada</brief_title>
	<detailed_description>This cross-sectional observational study design provide real-life data current management dyslipidemia high cardiovascular risk patient routine clinical practice . Canadian guideline recommend target LDL-C ≤2.0 mmol/L ( ≥50 % decrease ) treatment initiation high-risk patient . The recommend first line treatment statin therapy . Available data clearly indicate 50 % high risk patient achieve important target statin inadequacy intolerance lead non-adherence . Therefore program aim provide insight challenge Canadian physician face help high risk patient achieve guideline-recommended LDL-C .</detailed_description>
	<mesh_term>Dyslipidemias</mesh_term>
	<criteria>1 . Adults ≥ 18 year old 2 . High risk cardiovascular morbidity mortality ( least one follow ) : 1 . Clinical vascular disease : Coronary Artery Disease ( CAD ) : history myocardial infarction ( MI ) , Coronary artery bypass grafting ( CABG ) , percutaneous coronary intervention ( PCI ) , angiographic disease Cerebrovascular Disease ( CeVD ) : history cerebrovascular accident ( CVA ) transient ischemic attack ( TIA ) , carotid surgery Abdominal Aortic Aneurism ( AAA ) : history surgery/intervention Peripheral Arterial Disease ( PAD ) : history surgery/intervention 2 . Familial hypercholesterolemia define LDLC &gt; 5 mmol/L one : typical physical finding ( stigma ) tendon xanthomata , xanthelasma , arcus corneae personal history early cardiovascular disease family history early cardiovascular disease mark hyperlipidemia 3 . Receiving current optimal ( maximal maximal tolerate ) statin therapy least 3 month prior patient enrolment 4 . LDLC &gt; 2.0 mmol/L measure within 6 month patient enrolment date ( despite ) maximal tolerate statin therapy ( ± lipid modify therapy ) . 5 . Desire ability execute consent participate . Exclusion criterion : 1 . Current treatment PCSK9 inhibitor 2 . Participation investigational study 3 . Prior participation GOAL program</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>